Computational Study of Hydrogel Ring Device for Ocular Drug Delivery by Hanif, Sarah et al.
Department of Biological and Environmental Engineering 
Cornell University, Ithaca, NY 
     
©Sarah Hanif, Abigail Lim, Hilarie Sit, Wan Qing Melissa Tan, May 2018 
 
 
 
 
Computational Study of 
Hydrogel Ring Device for 
Ocular Drug Delivery 
 
 
 
 
BEE 4530/Group 03 
 
Sarah Hanif 
Abigail Lim 
Hilarie Sit 
Wan Qing Melissa Tan 
  
May 10, 2018 
  1 of 50 
Table of Contents 
1 Executive Summary .............................................................................................................. 3 
2 Introduction ........................................................................................................................... 4 
3 Problem Statement................................................................................................................ 5 
4 Design Objectives .................................................................................................................. 5 
5 Computational Model ........................................................................................................... 6 
5.1 Problem Formulation ...................................................................................................... 6 
5.2 Simplifications and Assumptions ................................................................................. 10 
6 Governing Equations and Boundary Conditions ............................................................. 11 
6.1 Heat Transfer ................................................................................................................ 11 
6.2 Laminar Flow ................................................................................................................ 12 
6.3 Diffusion Through Porous Media ................................................................................. 13 
6.4 Transport of Diluted Species ........................................................................................ 14 
7 Results .................................................................................................................................. 15 
7.1 Heat Transfer and Laminar Flow .................................................................................. 15 
7.2 Darcy’s Flow ................................................................................................................. 17 
7.3 Transport of a Diluted Species ...................................................................................... 17 
8 Mesh Convergence .............................................................................................................. 20 
9 Sensitivity Analysis ............................................................................................................. 23 
10 Validation......................................................................................................................... 26 
11 Optimization .................................................................................................................... 28 
12 Conclusion and Design Recommendations ................................................................... 32 
13 Appendix .......................................................................................................................... 33 
13.1 Geometry and Physical Dimensions ............................................................................. 33 
13.2 Input Parameters for Heat Transfer............................................................................... 34 
13.3 Input Parameters for Laminar Flow .............................................................................. 35 
13.4 Input Parameters for Darcy’s Flow ............................................................................... 35 
13.5 Input Parameters for Transport of a Diluted Species .................................................... 35 
13.6 Derivation of Initial Concentration of Ofloxacin in Hydrogel Ring............................. 36 
13.7 Concentration Surface Plots .......................................................................................... 37 
13.8 Mesh and Study Statistics ............................................................................................. 40 
13.8.1 Mesh for Computational Studies (1, 2, 3) ............................................................. 40 
13.8.2 Degrees of Freedom .............................................................................................. 42 
13.8.3 CPU and Memory ................................................................................................. 42 
  2 of 50 
13.9 Mesh Convergence........................................................................................................ 44 
13.10 Optimization ............................................................................................................. 46 
14 References ........................................................................................................................ 49 
 
  
  3 of 50 
1 Executive Summary 
 
Researchers have developed many different kinds of ocular drug delivery devices. However, most 
address anterior eye disorders—very few are designed specifically for the treatment of posterior 
eye diseases. A recently-developed hydrogel ring device is capable of delivering therapeutic 
quantities of the drug Ofloxacin to treat ocular infections at the back of the eye—a region typically 
difficult to access via systemic (e.g. ingestion of pills) and topical (e.g. eye drops) methods. Despite 
promising preliminary in vivo test results, much remains unknown about the precise drug transport 
pathway from the hydrogel ring to the posterior segment of the eye, as well as how design 
parameters may be altered to increase drug delivery efficiency. The aim of this work is to fully 
characterize the drug release and transport characteristics from the hydrogel, to ocular tissues 
(anterior and posterior), as well as provide a quantitative method for the optimization of various 
hydrogel ring design parameters. 
 
To achieve the abovementioned goals, we built a computational model using COMSOL 
Multiphysics to simulate the release of Ofloxacin from the hydrogel ring and to obtain the resulting 
drug distribution in ocular tissues at various time points. Using the model, we monitored the 
transient Ofloxacin concentration profile over the entire eye, for a treatment period of ten hours. 
Our results showed that while Ofloxacin diffuses to the anterior region much more quickly than to 
posterior tissues, Ofloxacin concentrations do successfully accumulate to therapeutic levels in the 
posterior tissues during the simulated ten-hour treatment period. This finding supports the 
therapeutic potential of the hydrogel ring for the treatment of posterior eye diseases.  
 
We also performed optimization analyses to determine the ideal set of hydrogel ring design 
parameters for the treatment of infections caused by three bacterial species commonly associated 
with ocular disorders: Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae. 
Preliminary findings suggest that the combination of an initial mass of 3𝑚𝑔/𝑚3 of Ofloxacin in 
the hydrogel and an Ofloxacin diffusivity of 3.11 ⋅ 10−9𝑚2/𝑠 in the hydrogel provide the best 
possible therapeutic outcome (from the range of values tested) for the treatment of E. coli and S. 
aureus infections. 
 
To our best knowledge, there is no existing computational model that simulates drug transport 
through the entire human eye from an ocular drug delivery device. We believe that our 
computational model will be highly useful for quantitative device characterization of the hydrogel 
ring, as well as in the optimization of the hydrogel ring design for the treatment of posterior eye 
disorders. This work may also serve as a model and reference for future computational work on 
ocular pharmacokinetics and/or ocular drug delivery devices.  
 
Keywords: ocular drug delivery, hydrogel, ocular ring, computational model, finite element 
analysis, COMSOL, ocular pharmacokinetics.  
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2 Introduction 
 
Despite many innovations over the last few decades, the search for safer, more effective and more 
convenient methods for ocular drug delivery remains an ongoing one [1]–[5] . As in the design of 
any drug delivery system, engineers must ensure: (1) biocompatibility of the drug delivery devices, 
(2) controlled, sustained release of drugs to target tissues, and (3) patient comfort [1], [5].  In 
addition to these general concerns, however, the design process for ocular drug delivery is further 
complicated by the complex physical composition of the human eye and its high sensitivity to 
foreign materials [1], [5], [6]. The relative impermeability of various ocular tissues (e.g. cornea 
and lens) also presents a major obstacle to efficient drug transport to posterior eye segments, 
especially in cases of bacterial infections or diseases that afflict regions of the eye that lie far from 
the cornea [1], [5], [6]. A high initial drug concentration in the delivery device may allow for drug 
levels in posterior tissues to accumulate to the Minimum Inhibitory Concentration (MIC) 
necessary for the effective treatment of bacterial infections. However, this approach may result in 
overly high (and potentially toxic) drug concentrations in ocular tissues nearer to the device during 
the treatment period [1], [5], [6]. 
 
[6] has recently reported on a new design for a hydrogel ring device that is capable of delivering 
therapeutic quantities of the bactericidal drug Ofloxacin to treat ocular infections at the back of the 
eye—a region typically difficult to access via systemic (e.g. ingestion of pills) and topical (e.g. eye 
drops) methods [1], [5]–[7]. The hydrogel ring is made from 2-Hydroxyethyl methacrylate 
(HEMA), a non-biodegradable polymer often employed in ophthalmic applications [6]. Unlike 
other drug-eluting hydrogel contact lens, the proposed hydrogel ring has a cornea-shaped cut-out 
in the center, so as to minimize contact with the cornea and thus reduce the risk of a drug 
overaccumulation in the cornea (which would lead to corneal disorders) [6]. Results from in vitro 
experiments on rabbits showed that the proposed hydrogel ring design (referenced as Ring 1 in [6]) 
provided the best therapeutic outcome when compared to controls (i.e. corneal lens, scleral/corneal 
lens, and topically-applied ofloxacin ophthalmic solution). The newly-developed hydrogel ring 
significantly increased Ofloxacin concentrations in posterior tissues, while reducing Ofloxacin 
concentrations in anterior regions [6]. These results strongly suggest the therapeutic potential of 
the hydrogel ring in the treatment of posterior eye disorders. 
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3 Problem Statement 
 
Notwithstanding the promising preliminary in vivo test results, much remains unknown about the 
precise drug transport pathway from the hydrogel to the posterior segment of the eye, as well as 
how design parameters may be altered to increase drug delivery efficiency. Prior in vivo 
experiments reported in [6] do not provide information on the spatial distribution of the delivered 
drug in ocular tissues during treatment. Without detailed characterization of the device, it is 
difficult for further design optimization to improve drug delivery efficiency, and to extend 
compatibility of the device with a wider range of pharmaceuticals that can be used to treat ocular 
diseases. In vivo experiments are also resource-intensive and time-consuming, and thus are not a 
feasible means for future optimization studies of the hydrogel ring design, especially if they require 
a high volume of iterations and trials. 
 
Unlike traditional means of in vivo and in vitro testing, computational models are less time-
consuming and resource-demanding, and also provides users with the flexibility to tune specific 
parameters and/or study specific biological processes [2], [8]–[10]. We thus designed and 
performed a  computational study of the drug-eluting hydrogel ring in [6], so as to provide 
quantitative device characterization and facilitate future design and optimization work. 
 
4 Design Objectives 
 
The specific goals of our computational study are as follows: 
• Build an anatomically-accurate computational model for ocular pharmacokinetics testing that 
incorporates the relevant physics influencing drug transport in the eye  
• Map the transient concentration profile of Ofloxacin over the entire eye for a treatment period 
of ten hours 
• Validate the computed solution (derived from the model) with experimental data in [6] 
• Optimize selected design parameters (initial mass of Ofloxacin loaded into hydrogel and 
diffusivity of Ofloxacin in the hydrogel) for optimal drug delivery to treat bacterial infections 
in the posterior region 
 
In achieving these design objectives, we hope that our computational model would be able to verify 
the therapeutic potential of the drug-eluting hydrogel ring to treat posterior segment ocular 
disorders, as well as facilitate further computational work on ocular pharmacokinetics and/or 
design of ocular drug delivery devices. 
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5 Computational Model 
 
5.1 Problem Formulation  
 
To address the above research goals, we developed a 2D-axisymmetric finite element 
computational model in COMSOL Multiphysics® Version 5.3 (COMSOL Inc., Stockholm, 
Sweden), which simulates the release of Ofloxacin from the hydrogel ring and provides the spatial 
distribution of Ofloxacin within ocular tissues during the treatment period (Figure 1). The model 
integrates existing computational work on drug diffusion within the anterior and posterior 
segments of the eye and incorporates four physics: (1) heat transport within the eye, (2) density-
driven natural convection flow of aqueous humor, (3) pressure-driven Darcy flow through the 
vitreous, and (4) transport of a diluted species within the entire eye (Figures 2, 3). We created the 
computational domain from scratch, using physical dimensions of various ocular tissues and the 
hydrogel ring provided in research literature (Figure 1). See Appendix 13.1 for physical 
dimensions used. 
 
We modeled the transport of diluted species (Ofloxacin) through all 13 sub-domains (Figures 1-
3). The main complexity in our model is due to the presence of spatially-varying, domain-specific 
velocities. To obtain the velocity profile in the anterior region of the eye (sub-domains 8 and 9), 
we coupled the solving of the heat equation with the solving of the Navier-Stokes equation. We 
applied the Boussinesq approximation (as seen from the temperature-dependent density term in 
Navier-Stokes equation) to reflect the buoyancy-driven natural convection of aqueous humor in 
sub-domains 8 and 9 (Figure 1) [8], [11]. Since aqueous humor (i.e. the fluid that flows within 
sub-domains 8 and 9) is supplied through the ciliary body (sub-domain 12) and drained through 
the trabecular meshwork (sub-domain 10), we specified sub-domain 12 as the inlet and sub-domain 
10 as the outlet. To solve for the velocity profile in the posterior region of the eye (sub-domains 
1-4), we solved Darcy’s Flow equation, which accounts for the pressure-driven flow through a 
static, incompressible, porous medium (i.e. the vitreous) [12].  
 
After solving for the respective velocities, we plugged the domain-specific velocity terms into the 
transport equation and solved the transport equation for all 13 sub-domains. 
 
  7 of 50 
 
 
Figure 1. Eye Anatomy with Labeled Sub-Domains. Our computational geometry consists of 
thirteen sub-domains with anatomically-accurate physical parameters and material properties 
derived from literature (see Appendix 13.1 to 13.5).  
 
 
 
 
 
 
 
 
10. Trabecular Meshwork 
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Figure 2. Domain-Specific Physics with Associated Boundary Conditions. (A) heat transfer 
(HT); (B) Darcy’s flow (DF); (C) transport of a diluted species (TDS); (D) laminar flow (LF). The 
labeled boundary conditions correspond to the boundary conditions described in Figure 3. 
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Figure 3. 2D Axisymmetric Computational Domain for COMSOL Implementation with 
Boundary Conditions for Each of the Four Physics Modules. HT: heat transfer (dependent 
variable 𝑻 ), DF: darcy-driven flow (dependent variables ?⃑? , 𝑷 ), LF: laminar flow (dependent 
variables ?⃑? , 𝑷 ), TDS: transport of a diluted species (dependent variable 𝒄 ). BCx: boundary 
condition x (1, 2, 3, or 4). Symmetry boundary condition is imposed on r=0mm for all four physics. 
r 
z  
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5.2 Simplifications and Assumptions 
 
In order to implement a 2D-axisymmetric geometry, we modeled the specific case in which the 
patient is in a supine position, i.e. gravity is pointing straight upwards relative to our computational 
geometry (Figure 1).  
 
We accounted for drug elimination into conjunctival lymphatics and episcleral veins from the 
scleral surface (sub-domain 1) using 𝑘𝑠𝑐 , a mass transfer coefficient at the scleral surface [12]. 
 
We accounted for drug loss to choroidal circulation (sub-domain 2) using the term 𝛾(𝑐𝑏𝑙 − 𝑐), 
where γ is the rate constant for volumetric drug transport across the blood vessels in the choroid 
and 𝑐𝑏𝑙 is the concentration of the drug in the blood circulation [12]. For simplicity, we assumed 
that 𝑐𝑏𝑙 = 0 and also ignored drug loss from the retina (sub-domain 3) due to active pumping by 
the retinal pigment epithelium and retinal capillaries. 
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6 Governing Equations and Boundary Conditions 
 
6.1 Heat Transfer 
 
Sub-Domains Involved 
All 
 
Governing Equation  
𝜌𝐶𝑝𝑣 ⋅ ∇𝑇 = ∇ ⋅ (𝑘∇𝑇) (1) 
 
(please see Appendix 13.2 for input parameters) 
 
Time Dependence 
Steady-state 
 
Boundary Conditions 
Flux boundary condition at the external boundary of sub-domain 8 (HT BC2, Figures 2A & 3), 
accounting for convection, radiative heat transfer, and heat loss by tear evaporation from the cornea, 
i.e. external boundary of sub-domain 8, to the surrounding air [8]: 
−?⃑? ⋅ (𝑘∇𝑇) = ℎ𝑎𝑚𝑏(𝑇 − 𝑇𝑎𝑚𝑏) + 𝜎𝜀(𝑇
4 − 𝑇𝑎𝑚𝑏
4 ) + 𝐸 (2) 
where 𝑇𝑎𝑚𝑏 = 298𝐾, ℎ𝑎𝑚𝑏 = 10𝑊/(𝑚
2 ⋅ 𝐾), 𝐸 = 40𝑊/𝑚2, 𝜀 = 0.975 [8] 
 
Flux boundary condition at all remaining external boundaries (HT BC1, Figures 2A & 3), 
assuming that the rest of the eye ball and the hydrogel ring are surrounded by blood vessels [8]: 
−?⃑? ⋅ (𝑘∇𝑇) = ℎ𝑏𝑙(𝑇 − 𝑇𝑏𝑙) (3)
where 𝑇𝑏𝑙 = 310𝐾, ℎ𝑏𝑙 = 65𝑊/(𝑚
2 ⋅ 𝐾) [8] 
 
Symmetry boundary condition at 𝑟 = 0 [8]: 
𝜕𝑇
𝜕𝑟
= 0 (4) 
  
  12 of 50 
6.2 Laminar Flow 
 
Sub-Domains Involved: 8, 9 (Figure 1) 
 
 
Governing Equations 
𝜌0(𝑣 ⋅ ∇)𝑣 = −∇𝑃 + 𝜇∇
2𝑣 + 𝜌0[1 − 𝛽(𝑇 − 𝑇𝑟𝑒𝑓)]𝑔  (5) 
∇(𝜌𝑣 ) = 0 (6) 
(please see Appendix 13.3 for input parameters) 
 
Time Dependence 
Steady-state 
 
Boundary Conditions 
No viscous stresses at outlet (LF BC1, Figures 2D & 3) [8]: 
𝜇(∇𝑣 + (∇𝑣 )𝑇) ⋅ ?⃑? = 0 (7) 
 
Parabolic velocity profile at inlet (LF BC2, Figures 2D & 3) [8]: 
𝑣 = −
𝑄
𝐴
⋅ 6 ⋅ 𝑠(1 − 𝑠)?⃑? , 0 ≤ 𝑠 ≤ 1 (8) 
 
Pressure boundary condition at point (6.422,4.539) (LF BC3, Figures 2D & 3) [8]: 
P = 2100Pa (9) 
 
No-slip boundary condition at all other boundaries/walls (LF BC4, Figures 2D & 3) [8]: 
𝑣 = 0 (10) 
 
Symmetry boundary condition at 𝑟 = 0 [8]: 
𝜕𝑣𝑟
𝜕𝑟
= 0 (11) 
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6.3 Diffusion Through Porous Media 
 
Sub-Domains Involved 
1, 2, 3, 4 (Figure 1) 
 
Governing Equation 
𝑣 = −
𝐾
𝜇
∇𝑃 (12) 
(please see Appendix 13.4 for input parameters) 
 
 
Time Dependence 
Steady-state 
 
Boundary Conditions  
Pressure boundary condition at internal boundary between sub-domains 4 and 9 (DF BC2, Figures 
2B & 3) [12]: 
𝑃 = 2000𝑃𝑎 (13) 
 
Pressure boundary condition at outer boundary of sub-domain 10 (DF BC1, Figures 2B & 3) [12]: 
𝑃 = 1300𝑃𝑎 (14) 
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6.4 Transport of Diluted Species 
 
Sub-Domains Involved 
All 
 
Governing Equation 
 
∂c
∂t
+ 𝑣 ⋅ ∇c − D ∇2 c = k (15) 
(please see Appendix 13.5 for input parameters) 
 
Time Dependence 
Transient 
 
Boundary Conditions (External)  
Concentration boundary condition at boundaries along the two short edges of the bulbar 
conjunctiva (sub-domain 5) and at the external boundary of sub-domain 13 (TDS BC1, Figures 2C 
& 3), assuming that these boundaries are exposed to internal blood circulation and any drug at the 
boundaries are promptly carried away by blood flow:  
𝑐 = 0 (16) 
 
Flux boundary condition at external boundary of sub-domain 1 (TDS BC2, Figures 2C & 3) [8], 
[12]:  
?⃑? (−𝐷 ⋅ ∇𝑐 + 𝑣 ⋅ 𝑐) = 𝑘𝑠𝑐𝑐 (17) 
where 𝑘𝑠𝑐 = 2.03 ⋅ 10
−7𝑚/𝑠 [8], [12] 
 
No flux boundary condition at all other external boundaries (TDS BC3, Figures 2C & 3) [8], [12]: 
∇c = 0 (18) 
  
 
Boundary Conditions (Internal) 
Flux continuity at all internal boundaries unless otherwise specified. 
 
Initial Condition 
All sub-domains except hydrogel ring: Concentration of Ofloxacin=0. 
Hydrogel ring: 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = 1.726 ⋅ 107𝑚𝑔/𝑚3 (see Appendix 13.6 for derivation) 
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7 Results 
 
We built a computational model using the input parameters, physics, boundary conditions and 
initial conditions listed above. All property values were sourced from research literature (either 
actual values or close substitutes). To shorten computation time, we ran three separate studies in 
this order: (1) Conjugated stationary study of heat transfer (entire eye) and laminar flow (aqueous 
humor), (2) Stationary study of Darcy’s flow through porous medium (vitreous, retina, choroid, 
sclera), (3) Time-dependent study of transport of a diluted species (entire eye). 
 
7.1 Heat Transfer and Laminar Flow 
 
We successfully obtained plots of steady-state temperature profile (Figure 4), velocity profile 
(Figure 5) and pressure distribution (not shown) that agree with results from literature [8], [11]. 
 
 
Figure 4. Surface Plot of Steady-State Temperature (K). Temperatures increase steadily from 
the surface of the eyeball (dark blue) to the back of the eye (dark red). The temperature profile that 
we have obtained here is in good agreement with the results from other research [8], [11]. 
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Figure 5. Steady-State Velocity (m/s) Field for Density-Driven Convective Flow of Aqueous 
Humor. The plot above depicts spatially-varying fluid velocities of aqueous humor in the anterior 
and posterior chambers, driven by spatially-varying, temperature-dependent density. The plot is in 
excellent agreement with results obtained in other ocular pharmacokinetics computational models 
[8], [11]. 
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7.2 Darcy’s Flow 
 
Using the Darcy’s Flow equation, we solved for fluid velocity in the posterior region of the eye. 
Figure 6 depicts the combined steady-state velocity profiles of aqueous humor flow in both the 
anterior and posterior regions. 
 
 
Figure 6. Steady-State Velocity (m/s) Field for Darcy’s Flow. The plot above depicts spatially-
varying fluid velocities of aqueous humor in the vitreous. Lengths of arrows in the arrow surface 
plot are proportional to fluid velocity at respective points, i.e. fluid velocity decreases as aqueous 
humor flows through the vitreous, retina, choroid and sclera. 
 
7.3 Transport of a Diluted Species 
 
Using the velocity profiles developed for buoyancy-driven flow (anterior and posterior chambers) 
and Darcy’s flow (vitreous, retina, choroid, sclera), we solved for the concentration profile of 
Ofloxacin in the eye. We found that while Ofloxacin diffuses much more quickly to the anterior 
region than the posterior region, Ofloxacin concentrations do successfully accumulate to 
therapeutic levels in the posterior tissues during the simulated ten-hour treatment period (Figures 
7,8). Please see Appendix Section 13.7 for concentration surface plots at additional time points. 
 
  18 of 50 
 
Figure 7. Ofloxacin Concentration Surface Plot at Time=1h (mg/m3). At time=1h after initial 
placement of the hydrogel ring, we observe that a considerable portion of the drug has diffused out 
of the hydrogel ring into the eye. Most of the released drug remains concentrated within the bulbar 
conjunctiva and the adjacent scleral region. 
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Figure 8. Ofloxacin Concentration Surface Plot at Time-8h (mg/m3). Compared to Figure 7, 
concentration in the bulbar conjunctiva (red region) has decreased dramatically. More drug has 
diffused into other sub-domains and regions of the eye. 
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8 Mesh Convergence 
 
To minimize spatial discretization error in our model, we performed mesh convergence analysis 
to determine the smallest possible maximum mesh element size, below which the solution is no 
longer mesh-dependent (i.e. no significant change to solution with an increase in the number of 
mesh elements). 
 
We ran our model for a large range of maximum mesh element sizes (from 0.0115mm to 0.5mm) 
and graphed on the same plot the concentration of Ofloxacin at time=1h along a pre-selected line 
that passes through points (0, 2.5) and (6.445, 2.5) for all mesh sizes. Figure 9 shows a sub-
section of the plot for which there is greatest divergence between the individual data series.  
 
 
 
Figure 9. Mesh Convergence Analysis (Time=1h), Convergence at 0.0175mm. The number in 
parentheses indicates the total number of triangular mesh elements in the mesh corresponding to 
the specific maximum mesh element size. For each maximum mesh element size, we plotted 
Ofloxacin concentration along a 2D Cut-Line (from (0, 2.5) to (6.445, 2.5)). This plot can be 
divided into three broad bands: the smallest mesh sizes (0.0115mm-0.0175mm) form the topmost 
band, intermediate mesh sizes (0.01775mm-0.03mm) form the middle band, the largest mesh sizes 
(0.04mm-0.5mm) form the bottom band. Figure 9 is reproduced in Appendix 13.9 in full-page size 
for greater clarity. 
 
We observe that the plot of concentrations along the 2D Cut-Line oscillates in the same band for 
maximum mesh element sizes of 0.0175mm and below (Figure 9), suggesting that mesh 
convergence has occurred using a mesh with 1626005 triangular elements.  
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To confirm this result, we performed further mesh convergence analysis by comparing the average 
Ofloxacin concentration at time=1h in posterior eye tissues (i.e. retina, sclera) for five different 
meshes: maximum mesh element size=0.014mm (2541834 elements), 0.015mm (2219008 
elements), 0.0175mm (1626005 elements), 0.02mm (940917 elements), and 0.5mm (55616 
elements). We focused on posterior eye tissues since we are most interested in drug delivery to the 
posterior segment of the eye from the hydrogel ring device. Figures 10 and 11 show the results of 
this analysis. As expected, mesh convergence is observed for all three meshes with a number of 
elements greater than or equal to 1626005 (corresponding to maximum mesh element 
size=0.0175mm). 
 
All computational results and solutions in this paper, unless otherwise stated, were obtained using 
a mesh with maximum mesh element size of 0.0175mm (1626005 elements), i.e. point of 
convergence. 
 
 
 
Figure 10. Average Ofloxacin Concentration in Sclera (mg/m3) vs. Number of Mesh Elements. 
Mesh convergence is observed for meshes with number of elements greater than or equal to 
1626005 (corresponding to maximum mesh element size=0.0175mm). 
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Figure 11. Average Ofloxacin Concentration in Retina (mg/m3) vs. Number of Mesh 
Elements. Mesh convergence is observed for meshes with number of triangular elements greater 
than or equal to 1626005 (corresponding to maximum mesh element size=0.0175mm). 
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9 Sensitivity Analysis 
 
In our model, we made reasonable assumptions for values of material properties and physical 
parameters that were unavailable in literature. To determine the effect of potential errors in our 
assumed values on the computed solution, we performed sensitivity analysis on four main 
parameters that we believe may contain the most error (i.e. when information for very close 
substitutes are also unavailable) and/or is closely related to Ofloxacin concentration in sub-
domains of interest (i.e. the retina and cornea): (1) Ofloxacin diffusivity in hydrogel ring, (2) 
Ofloxacin diffusivity in retina, (3) specific heat capacity of hydrogel, and (4) thermal conductivity 
of hydrogel. We varied these four parameters by ±10% and ±25% and calculated the changes in 
computational results of interest (i.e. average Ofloxacin concentration in the retina and in the 
cornea, at times t=1h and t=8h). 
 
Sensitivity analysis revealed that these results of interest are highly sensitive to changes in the 
diffusivity of Ofloxacin in the hydrogel ring (Figure 12). This result is unsurprising, given that 
Ofloxacin diffusivity in the hydrogel directly governs the rate of release of Ofloxacin into ocular 
tissues. Average Ofloxacin concentrations in the retina and cornea at both time points (t=1h and 
t=8h) are inversely related to Ofloxacin diffusivity in the hydrogel (Figure 12). A possible 
explanation for this relationship is that as Ofloxacin diffusivity in the hydrogel increases, more 
drug is lost to blood circulation via the exposed external boundary of the hydrogel ring. 
Consequently, less of the drug that was initially loaded into the hydrogel actually enters the ocular 
tissues (see Section 6.4). 
 
Additional analysis showed that while changes in Ofloxacin diffusivity in the retina produced 
corresponding changes in average Ofloxacin concentration in the retina at both time points, the 
average concentration of Ofloxacin in the cornea is largely insensitive to these changes (Figure 
13). This result may suggest that drug transport in the anterior region of the eye is largely 
unaffected by changes in changes to material properties of the posterior region.  
 
In contrast, we found that changes in both specific heat capacity and thermal conductivity of the 
hydrogel produced no change in average Ofloxacin concentration in the retina and cornea at both 
time points. 
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Figure 12. Change in Average Ofloxacin Concentration (%) vs. Change in Ofloxacin 
Diffusivity in Hydrogel (%). Average Ofloxacin concentrations in both the retina and cornea at 
both time points (t=1h and t=8h) increase as Ofloxacin diffusivity in the hydrogel decreases, and 
vice versa. Average Ofloxacin concentrations in the retina and cornea at time t=8h are highly 
sensitive to changes in Ofloxacin diffusivity in the hydrogel: a -25% change in Ofloxacin 
diffusivity produces 24.67% and 28.45% increases in average Ofloxacin concentration in the retina 
and cornea, respectively.  
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Figure 13. Change in Average Ofloxacin Concentration (%) vs. Change in Ofloxacin 
Diffusivity in Retina (%). Average Ofloxacin concentration in the retina at both time points (t=1h 
and t=8h) are highly sensitive (and directly related) to changes in Ofloxacin diffusivity in the retina. 
In contrast, changes in Ofloxacin diffusivity in the retina produced negligible changes in terms of 
average Ofloxacin concentration in the cornea. 
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10 Validation 
 
We validated our computational results by comparing average Ofloxacin concentration in various 
ocular tissues at time=1h with the experimental data from [6]. From Table 1, we observe that while 
there is good agreement between computed and experimental Ofloxacin concentration in the 
combined retina + choroid tissues, there are significant differences between experimental and 
computational results for other ocular tissues, especially in the bulbar conjunctiva and sclera 
(Table 1). Given that the experimental data from [6] is derived from rabbits while our 
computational study is based on a human eye model, we suspect that the large discrepancies in the 
spatial distribution of Ofloxacin concentrations between the computed results and experimental 
data may be largely attributed to differences in organization and relative sizes of anterior regions 
of rabbit and human eyes [13]. 
 
The above comparison, however, suggests that our model remains useful in modeling drug 
transport to posterior eye segments, i.e. the retina and choroid, and in predicting accumulated drug 
levels in posterior eye tissues.  
 
Table 1. Comparison of computational results with experimental data.  
 Ofloxacin Concentration (𝒎𝒈/𝒎𝟑) 
 Cornea Bulbar 
Conjunctiva 
Sclera Aqueous 
Humor 
Retina + 
Choroid 
[6] 13000 (3.73) 29900 (8.59) 7770 (2.23) 3800 (1.09) 3480 (1) 
Group03 
63814 (17.0) 
1545100 
(412) 
243510 
(65.0) 
8364.1 
(2.23) 3746.9 (1) 
Note: Number in parentheses indicates ratio of Ofloxacin concentration in a particular ocular 
tissue relative to that in the retina + choroid (combined). 
 
To provide further validation for our computational model, we compared the cumulative amount 
of Ofloxacin released from the hydrogel over time as obtained in [6], with that calculated using 
our model (Figure 14). A direct comparison between our model results and data from [6] reveals 
that the cumulative drug release profile obtained through our model is of the same general shape 
as that obtained experimentally (Figure 14, blue vs. red plots), but the profile obtained via 
modeling is much steeper (Figure 14). Given the high sensitivity of the computed solution to 
changes in Ofloxacin diffusivity in the hydrogel (see Section 8), we hypothesized that the 
difference in experimental and computed drug release profiles may be due to an overestimation in 
the value for Ofloxacin diffusivity in the hydrogel, in our model.  
 
This hypothesis is supported by the green plot in Figure 14, obtained by decreasing Ofloxacin 
diffusivity in the hydrogel by one order of magnitude from the original value used. Compared to 
the original red plot, the green plot provides a much better fit to the experimentally-derived drug 
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release profile (Figure 14). Here, we note that our model is based on several approximations of the 
thermal and drug transport properties of the hydrogel ring (due to unavailability of precise data 
and detailed specifications from literature). We thus believe that the fit between our model and 
experimental data can be further improved with further finetuning of assumed physical parameter 
values and material properties.  
 
 
 
Figure 14. Cumulative Amount of Drug Released (mg) vs. Time (h). This figure compares the 
computed drug release profile from times t=0h to t=8h with that based on the data in [6]. There is 
a sharp burst release at very early time points (t<0.5h), followed by a steady release at subsequent 
time points. The green plot is obtained by decreasing Ofloxacin diffusivity in the hydrogel by one 
order of magnitude (from the value used to obtain the red plot).  
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11 Optimization 
 
To demonstrate the potential of the computational model for design and optimization studies, we 
performed a simple optimization analysis to determine the optimal hydrogel ring design for the 
treatment of ocular infections caused by various species of bacteria: Escherichia coli, 
Staphylococcus aureus, and Streptococcus pneumoniae. We optimized two design parameters: (1) 
initial mass of Ofloxacin loaded into the hydrogel ring (IM), and (2) Ofloxacin diffusivity in the 
hydrogel (HD).  
 
The ideal hydrogel ring design would be able to deliver a sustained release of Ofloxacin, as well 
as maintain Ofloxacin concentrations in the cornea and the retina within the therapeutic window 
for as long as possible. The upper bound of the therapeutic window is the Ofloxacin concentration 
that is considered toxic for a specific ocular tissue, and the lower bound is the Minimum Inhibitory 
Concentration for 90% of isolates of a particular bacterial species (i.e. MIC90) [14].  
 
We developed an objective function, which can be used to evaluate the therapeutic effectiveness 
of various combinations of IM and HD (Equation 19). The best combination of IM and HD is one 
that maximizes the value of the objective function value, 𝐽 . Further information on the sub-
functions 𝐹𝐶 and 𝐹𝑅 can be found in the Appendix 13.10.  
 
𝐽 = ∑ 𝐹𝐶(𝑐𝑖) + ∑ 𝐹𝑅
8405
𝑗=1
12244
𝑖=1
(𝑐𝑗) (19) 
 
We ran the model for 16 different pairs of IM values and HD values (i.e. 4 different values each). 
From our results, we found that for constant values of MIC90 and IM, 𝐽 decreases as HD decreases 
(Appendix 13.10). We thus selected cases 1, 5, 9, and 13 (of which the value of HD is the highest 
of the four values tested) for further analysis (Appendix 13.10). 
 
We found that the combination of 𝐻𝐷 = 3.11 ⋅ 10−9𝑚2/𝑠  and 𝐼𝑀 = 3𝑚𝑔 is most ideal for the 
treatment of both E. coli (Figure 15) and S. aureus infections (Figure 16). We were not able to 
obtain a satisfactorily optimized combination of HD and IM values for the treatment of S. 
pneumoniae infections (Figure 17)—it is possible that the optimal combination may lie outside the 
relatively narrow range that we tested for this sample calculation. 
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Figure 15. Objective Function Value vs. Time (h). This plot is for 𝑀𝐼𝐶90 = 250𝑚𝑔/𝑚
3, i.e. 
treatment of E. coli. At earlier times, objective function values are very negative (i.e. far from 
therapeutic goal) because very little drug has diffused to the cornea and retina. At later times, the 
increase in objective function value due to the accumulation of drug in the retina may be offset by 
the decrease in objective function value due to an excessive accumulation in the cornea (past toxic 
threshold). 𝐼𝑀 = 3𝑚𝑔 appears to provide a balanced and most-ideal therapeutic outcome: it yields 
the highest/second-highest objective function value for 80% of the treatment time. 
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Figure 16. Objective Function Value vs. Time (h). This plot is for 𝑀𝐼𝐶90 = 1000𝑚𝑔/𝑚
3, i.e. 
treatment of S. aureus. At earlier times, objective function values are very negative (i.e. far from 
therapeutic goal) because very little drug has diffused to the cornea and retina. At later times, the 
increase in objective function value due to the accumulation of drug in the retina may be offset by 
the decrease in objective function value due to an excessive accumulation in the cornea (past toxic 
threshold). 𝐼𝑀 = 3𝑚𝑔 appears to provide a balanced and most-ideal therapeutic outcome: it yields 
the highest/second-highest objective function value for approximately 80% of the treatment time. 
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Figure 17. Objective Function Value vs. Time (h). This plot is for 𝑀𝐼𝐶90 = 2000𝑚𝑔/𝑚
3, i.e. 
treatment of S. pneumoniae. At earlier times, objective function values are very negative (i.e. far 
from therapeutic goal) because very little drug has diffused to the cornea and retina. At later times, 
the increase in objective function value due to the accumulation of drug in the retina may be offset 
by the decrease in objective function value due to an excessive accumulation in the cornea (past 
toxic threshold). There is no clear optimized IM for 𝑀𝐼𝐶90 = 2000𝑚𝑔/𝑚
3 since the objective 
function values are very negative for all IM values tested. 
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12 Conclusion and Design Recommendations 
 
We have completed a computational study of a hydrogel ring device for ocular drug delivery and 
achieved the design objectives of our study. Using our computational model, we determined the 
spatial and temporal drug distribution in ocular tissues during treatment with the hydrogel ring 
device. Our modeling results validate the therapeutic potential of the hydrogel ring in the treatment 
of posterior segment ocular disorders. We have also completed a preliminary optimization study 
to optimize the hydrogel ring design parameters for the therapeutic treatment of three different 
types of bacterial infections.  
 
Further studies on the hydrogel ring device may use our computational model to determine the 
compatibility of the hydrogel ring with other ocular pharmaceuticals, as well as optimize a wider 
range of design parameters, e.g. physical dimensions of the hydrogel ring. Ultimately, modeling 
results must also be corroborated by additional experimental data to support the use of the hydrogel 
ring device in clinical applications.  
 
Future computational work on ocular pharmacokinetics in general may finetune our model to 
account for more processes associated with drug transport, including (but not limited to) lacrimal 
tear drainage [9], vitreous motion due to eye rotations [15], and drug loss due to active pumping 
by the retinal pigment epithelium and retinal capillaries [12]. Future studies may also consider 
adapting our 2D-axisymmetric model into a 3D model in order to model the case in which the 
patient is standing upright (i.e. not lying down, as assumed in our model). A 3D model is necessary 
for this scenario, since the axis about which the gravitational force vector is rotationally symmetric 
is not the same as the axis about which eye geometry is rotationally symmetric. 
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13 Appendix 
 
13.1 Geometry and Physical Dimensions 
 
As we were unable to obtain a satisfactory human eye computational model from research 
literature, we constructed an anatomically-accurate computational geometry based on physical 
dimensions obtained from various sources [6], [9], [12], [16] (Figure A1). 
 
 
 
Figure A1. Labeled Computational Geometry and Physical Dimensions. We created the 
computational geometry using SolidWorks® (Dassault Systèmes, Vélizy-Villacoublay, France), 
with all physical dimensions (in mm) derived from literature [6], [9], [12], [16]. 
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13.2 Input Parameters for Heat Transfer 
 
Table 2. Thermal Properties Specified for Computational Sub-Domains. 
Sub-Domain 𝐤(
𝐖
𝐦⋅𝐤
)  𝐜 (
𝐉
𝐤𝐠⋅𝐊
)  𝛒 (
𝐤𝐠
𝐦𝟑
)  𝐮(
𝐦
𝐬
)  Source 
Cornea 0.58 4178 1050 0 [8] 
Vitreous 0.603 4178 1000 0 [8] 
Sclera 1.0042 3180 1100 0 [8] 
Retina* 1.0042 3180 1100   
Choroid* 1.0042 3180 1100   
Bulbar 
Conjunctiva* 
1.0042 3180 1100   
Iris 1.0042 3180 1100 0 [8] 
Aqueous 
Humor 
(fluid) 
0.58 3997 
𝜌(𝑇) 
(coupled in 
laminar flow) 
u  
(solved in laminar 
flow) 
[8] 
Ciliary Body 1.0042 3180 1100 0 [8] 
Lens 0.4 3000 1050 0 [8] 
Trabecular 
Meshwork 
1.0042 3180 1100 0 [8] 
Hydrogel 0.5^ 1150# 1403.83404 0 
k: [17] 
c: [18] 
𝝆: [6] 
*assumed to have the same input parameters as the sclera 
^approximated based on range of thermal conductivities for polyacrylamide hydrogels 
#approximated to be the same as the heat conductivity of water in a poly(methy1methacrylate) 
hydrogel membrane  
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13.3 Input Parameters for Laminar Flow 
 
Table 3. Input Parameters Specified in Computational Model for Laminar Flow Physics. 
Input Parameter Value Source 
𝜌0  996 [
𝑘𝑔
𝑚3
]  [8] 
𝜇  0.00074 [𝑃𝑎 ⋅ 𝑠]  [8] 
𝛽  0.000337 [
1
𝐾
]  [8] 
𝑔  9.81 [
𝑚
𝑠2
]  [8] 
𝑇𝑟𝑒𝑓  307 [𝐾]  [8] 
𝑄𝑎ℎ   2.4 [
𝜇𝐿
𝑚𝑖𝑛
]  [8] 
𝐴𝑐𝑏   34.04 [𝑚𝑚
2]  [8] 
 
13.4 Input Parameters for Darcy’s Flow 
 
Table 4. Input Parameters Specified in Computational Model for Darcy’s Flow Physics. 
Sub-Domain 
𝐊
𝛍 
 (𝐜𝐦𝟐/𝐏𝐚 ⋅ 𝐬)  𝜺 Source 
Vitreous 8.4 ⋅ 10−7  0.5* [12] 
Retina 2.36 ⋅ 10−11  0.5* [12] 
Choroid 1.5 ⋅ 10−11  0.5* [12] 
Sclera 1.5 ⋅ 10−11  0.5* [12] 
*assumed porosity value 
 
13.5 Input Parameters for Transport of a Diluted Species 
 
Table 5. Input Parameters Specified in Computational Model for Species Transport. 
Sub-Domain Diffusion Coefficient for Ofloxacin (𝐜𝐦𝟐/𝐬) Source 
Cornea 1 ⋅ 10−7  [7] 
Vitreous 1 ⋅ 10−5  [7] 
Sclera 1 ⋅ 10−7  [7] 
Bulbar Conjunctiva* 1 ⋅ 10−7   
Iris 1 ⋅ 10−6  [7] 
Aqueous Humor 1 ⋅ 10−4  [7] 
Ciliary Body 1 ⋅ 10−7  [7] 
Lens 1 ⋅ 10−7  [7] 
Trabecular Meshwork 1 ⋅ 10−7  [7] 
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Retina^ 1 ⋅ 10−8   
Choroid* 1 ⋅ 10−7   
Hydrogel# 3.11 ⋅ 10−11  [19] 
*assumed to be the same as the diffusion coefficient in sclera [8] 
^assumed to be 0.1 of diffusion coefficient in sclera 
#approximated to be the same as that of Levofloxacin (left-sided isomer of Ofloxacin) in 98/2 (w/w) 
2-hydroxyethyl methacrylate (HEMA)/ Poly(vinylpyrrolidone) (PVP) hydrogel  
 
Table 6. Domain-Specific Inputs for ?⃑?  and k in Transport Equation. 
Sub-Domain ?⃑?   𝐤  Source 
Sclera Darcy Flow (see 6.3) γ(cbl − c), 𝛾 = 1.98 ⋅ 10
−5𝑠−1, cbl = 0 [12] 
Choroid Darcy Flow (see 6.3) γ(cbl − c), 𝛾 = 1.98 ⋅ 10
−5𝑠−1, cbl = 0 [12] 
Retina Darcy Flow (see 6.3)  0 [12] 
Vitreous Darcy Flow (see 6.3) 0 [12] 
Bulbar 
Conjunctiva 
0 0 [12] 
Lens 0 0 [8] 
Cornea 0 0 [8] 
Anterior 
Chamber 
Buoyancy Driven 
Flow (see 6.2) 
0 [8] 
Posterior 
Chamber 
Buoyancy Driven 
Flow (see 6.2) 
0 [8] 
Trabecular 
Meshwork 
   
Iris 0 0 [8] 
Ciliary Body 0 0 [8] 
Hydrogel 0 0 [6] 
 
 
13.6 Derivation of Initial Concentration of Ofloxacin in Hydrogel Ring 
Given in [6]: Hydrogel ring is 38wt% water, total weight of hydrogel ring is 183mg, weight of 
Ofloxacin loaded into hydrogel ring is 1200𝜇𝑔. 
Assume: Density of water is 1𝑔/𝑐𝑚3 = 1𝑔/𝑚𝐿 
 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑖𝑛 ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑙 𝑟𝑖𝑛𝑔 = 0.38 ⋅ 183𝑚𝑔 = 69.54𝑚𝑔 = 69.54 ⋅ 10−3𝑚𝐿 
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑂𝑓𝑙𝑜𝑥𝑎𝑐𝑖𝑛 𝑖𝑛 ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑙 𝑟𝑖𝑛𝑔 =
1200 ⋅ 10−3𝑚𝑔
69.54 ⋅ 10−3𝑐𝑚3 (
1𝑚3
106𝑐𝑚3
)
= 17256255.39𝑚𝑔/𝑚3 
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13.7 Concentration Surface Plots 
 
The following figures show the concentration surface plots for times t=0h to t=10h (Figures A2, 
A3). 
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Figure A2. Ofloxacin Concentration Surface Plot at Time=0h to Time=5h (mg/m3). Ofloxacin 
diffuses out of the hydrogel and enters the anterior first before diffusing to the posterior region. 
Most of the drug has diffused out of the hydrogel by time=5h. 
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Figure A3. Ofloxacin Concentration Surface Plot at Time=6h to Time=10h (mg/m3). 
Ofloxacin begins to accumulate in posterior segment tissues at later times. Ofloxacin 
concentrations in various sub-domains approach steady-state at time=10h.  
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13.8 Mesh and Study Statistics 
 
13.8.1 Mesh for Computational Studies (1, 2, 3) 
Mesh type: Free triangular 
Total number of triangular elements: 1626005 
Number of edge elements: 9056 
Number of vertex elements: 43 
Number of mesh vertices: 814387 
 
 
Figure A4. Zoom-in of Mesh of Vitreous, Retina, Choroid, and Sclera. Vitreous (V); retina 
(R); choroid (C); sclera (S). The maximum mesh element size is 0.0175mm. 
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Figure A5. Zoom-In of Mesh of Hydrogel Ring. Hydrogel ring (H); bulbar conjunctiva (BC); 
sclera (S). The maximum mesh element size is 0.0175mm. 
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Figure A6. Zoom-In of Mesh in Between Lens and Iris. Lens (L); iris (I). The maximum mesh 
element size is 0.0175mm.  
 
13.8.2 Degrees of Freedom 
Pressure (comp1.p): 2691219 
Concentration (comp1.c2): 814387 (plus 15440 internal DOFs) 
Temperature (comp1.T): 3254778 (plus 30785 internal DOFs) 
Velocity field (comp1.u): 113680 (plus 1 internal DOFs) 
Pressure (comp1.p2): 56840 
Total: 6930904 (plus 46226 internal DOFs) 
 
13.8.3 CPU and Memory 
Total Runtime (1 run) = 591s + 50s + 1704s = 2345s = 39 minutes, 5 seconds 
 
Physical memory usage (Study 1 of 3) = 11.04 GB 
Physical memory usage (Study 2 of 3) = 6.46 GB 
Physical memory usage (Study 3 of 3) = 5.28 GB 
 
Virtual memory usage (Study 1 of 3) = 12.9 GB 
Virtual memory usage (Study 2 of 3) = 8.04 GB 
L 
I 
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Virtual memory usage (Study 3 of 3) = 6.47 GB 
===================== Opened Group03_final.mph =========================== 
<---- Compile Equations: Stationary in Study 1/Solution 1 (sol1) --------------- 
Started at 9-May-2018 19:29:29. 
Geometry shape order: Linear 
Running on Intel(R) Core(TM) i7-6700 CPU at 3.40 GHz. 
Using 8 cores on 1 socket. 
Available memory: 16.27 GB. 
Time: 7 s. 
Physical memory: 1.73 GB 
Virtual memory: 1.89 GB 
Ended at 9-May-2018 19:29:35. 
----- Compile Equations: Stationary in Study 1/Solution 1 (sol1) --------------> 
<---- Stationary Solver 1 in Study 1/Solution 1 (sol1) ------------------------- 
Started at 9-May-2018 19:29:39. 
Segregated solver 
Number of degrees of freedom solved for: 3425298 (plus 30786 internal DOFs). 
Solution error estimates for segregated groups 
0.00078, 2.7e-008 
Residual error estimates for segregated groups 
0.014, 1.6e-006 
Solution time: 591 s. (9 minutes, 51 seconds) 
Physical memory: 11.04 GB 
Virtual memory: 12.9 GB 
Ended at 9-May-2018 19:39:30. 
----- Stationary Solver 1 in Study 1/Solution 1 (sol1) ------------------------> 
===================================================================== 
<---- Compile Equations: Stationary in Study 2/Solution 2 (sol2) --------------- 
Started at 9-May-2018 19:40:42. 
Geometry shape order: Linear 
Running on Intel(R) Core(TM) i7-6700 CPU at 3.40 GHz. 
Using 8 cores on 1 socket. 
Available memory: 16.27 GB. 
Time: 5 s. 
Physical memory: 2.81 GB 
Virtual memory: 4.01 GB 
Ended at 9-May-2018 19:40:47. 
----- Compile Equations: Stationary in Study 2/Solution 2 (sol2) --------------> 
<---- Stationary Solver 1 in Study 2/Solution 2 (sol2) ------------------------- 
Started at 9-May-2018 19:40:50. 
Linear solver 
Number of degrees of freedom solved for: 2691219. 
Solution time: 50 s. 
Physical memory: 6.46 GB 
Virtual memory: 8.04 GB 
Ended at 9-May-2018 19:41:40. 
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----- Stationary Solver 1 in Study 2/Solution 2 (sol2) ------------------------> 
<---- Compile Equations: Time Dependent in Study 3/Solution 3 (sol3) ----------- 
Started at 9-May-2018 19:42:22. 
Geometry shape order: Linear 
Running on Intel(R) Core(TM) i7-6700 CPU at 3.40 GHz. 
Using 8 cores on 1 socket. 
Available memory: 16.27 GB. 
Time: 5 s. 
Physical memory: 3.25 GB 
Virtual memory: 4.21 GB 
Ended at 9-May-2018 19:42:26. 
----- Compile Equations: Time Dependent in Study 3/Solution 3 (sol3) ----------> 
<---- Time-Dependent Solver 1 in Study 3/Solution 3 (sol3) --------------------- 
Started at 9-May-2018 19:42:29. 
Time-dependent solver (BDF) 
Number of degrees of freedom solved for: 814387 (plus 15440 internal DOFs). 
Solution time: 1704 s. (28 minutes, 24 seconds) 
Physical memory: 5.28 GB 
Virtual memory: 6.47 GB 
Ended at 9-May-2018 20:10:53. 
----- Time-Dependent Solver 1 in Study 3/Solution 3 (sol3) --------------------> 
 
13.9 Mesh Convergence 
 
Figure 9 is reproduced on the following page in full-page size for greater clarity. 
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13.10  Optimization 
 
The complete objective function is as follows: 
 
𝐽 = ∑ 𝐹𝐶(𝑐𝑖) + ∑ 𝐹𝑅
8405
𝑗=1
12244
𝑖=1
(𝑐𝑗) (19) 
 
where 
 
𝐹𝐶(𝑐𝑖) = {
0, 𝑖𝑓 𝑐𝑖 < 𝑀𝐼𝐶90
1, 𝑖𝑓 𝑀𝐼𝐶90 ≤ 𝑐𝑖 ≤ 2200𝑚𝑔/𝑚
3
−
𝑐𝑖
2200𝑚𝑔/𝑚3
, 𝑖𝑓 𝑐𝑖 > 2200𝑚𝑔/𝑚
3
 
 
 
𝐹𝑅(𝑐𝑗) = {
−
𝑀𝐼𝐶90
𝑐𝑟
, 𝑖𝑓 𝑐𝑗 < 𝑀𝐼𝐶90
1, 𝑖𝑓 𝑐𝑗 ≥ 𝑀𝐼𝐶90
 
 
 
𝑀𝐼𝐶90 = {
250𝑚𝑔/𝑚3, 𝐸𝑠𝑐ℎ𝑒𝑟𝑖𝑐ℎ𝑖𝑎 𝑐𝑜𝑙𝑖
1000𝑚𝑔/𝑚3,   𝑆𝑡𝑎𝑝ℎ𝑦𝑙𝑜𝑐𝑜𝑐𝑐𝑢𝑠 𝑎𝑢𝑟𝑒𝑢𝑠
2000𝑚𝑔/𝑚3, 𝑆𝑡𝑟𝑒𝑝𝑡𝑜𝑐𝑜𝑐𝑐𝑢𝑠 𝑝𝑛𝑒𝑢𝑚𝑜𝑛𝑖𝑎𝑒
 
 
𝐹𝐶  is the sub-function that applies to all 12244 nodes in the cornea; 𝑐𝑖  refers to Ofloxacin 
concentration at the 𝑖𝑡ℎ node in the cornea. 𝐹𝑅 is the sub-function that applies to all 8405 nodes in 
the retina; 𝑐𝑗 refers to Ofloxacin concentration at the 𝑗
𝑡ℎ node in the retina. 
 
The toxic threshold level of Ofloxacin in the cornea is 2200𝑚𝑔/𝑚3 [14]. There is negligible 
retinal toxicity of Ofloxacin [20]. 
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Table 7. Objective Function Values for MIC90 = 𝟐𝟓𝟎𝒎𝒈/𝒎𝟑. 
Case 
Initial Mass 
(mg) 
Diffusivity 
(m2/s) 
t=1h t=8h 
1 0.5 3.11 ⋅ 10−9  -7613.0291 -8405 
2 0.5 3.11 ⋅ 10−10  -149625.24 -96768.292 
3 0.5 3.11 ⋅ 10−11  -99299.33 -86565.268 
4 0.5 3.11 ⋅ 10−12  -131845.09 -351291.28 
5 1.2 3.11 ⋅ 10−9  -9554.58 3850 
6 1.2 3.11 ⋅ 10−10  -36888.3 -19743.1 
7 1.2 3.11 ⋅ 10−11  -236071 -218326 
8 1.2 3.11 ⋅ 10−12  -315792 -854867 
9 3 3.11 ⋅ 10−9  -12963.9 8294 
10 3 3.11 ⋅ 10−10  -90457.6 -55203.4 
11 3 3.11 ⋅ 10−11  -587489 -558421 
12 3 3.11 ⋅ 10−12  -788077 -2149776 
13 5 3.11 ⋅ 10−9  -17705.2 9628.773 
14 5 3.11 ⋅ 10−10  -149625 -96768.3 
15 5 3.11 ⋅ 10−11  -977976 -936306 
16 5 3.11 ⋅ 10−12  -1315077 -3588563 
 
Table 8. Objective Function Values for MIC90 = 𝟏𝟎𝟎𝟎𝒎𝒈/𝒎𝟑. 
Case 
Initial Mass 
(mg) 
Diffusivity 
(m2/s) 
t=1h t=8h 
1 0.5 3.11 ⋅ 10−9  -7613.0291 -8405 
2 0.5 3.11 ⋅ 10−10  -149625.24 -96768.292 
3 0.5 3.11 ⋅ 10−11  -99299.33 -86565.268 
4 0.5 3.11 ⋅ 10−12  -131845.09 -351291.28 
5 1.2 3.11 ⋅ 10−9  -9554.58 3850 
6 1.2 3.11 ⋅ 10−10  -36888.3 -19743.1 
7 1.2 3.11 ⋅ 10−11  -236071 -218326 
8 1.2 3.11 ⋅ 10−12  -315792 -854867 
9 3 3.11 ⋅ 10−9  -12963.9 8294 
10 3 3.11 ⋅ 10−10  -90457.6 -55203.4 
11 3 3.11 ⋅ 10−11  -587489 -558421 
12 3 3.11 ⋅ 10−12  -788077 -2149776 
13 5 3.11 ⋅ 10−9  -17705.2 9628.773 
14 5 3.11 ⋅ 10−10  -149625 -96768.3 
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15 5 3.11 ⋅ 10−11  -977976 -936306 
16 5 3.11 ⋅ 10−12  -1315077 -3588563 
 
Table 9. Objective Function Values for MIC90 = 𝟐𝟎𝟎𝟎𝒎𝒈/𝒎𝟑. 
Case 
Initial Mass 
(mg) 
Diffusivity 
(m2/s) 
t=1h t=8h 
1 0.5 3.11 ⋅ 10−9  -7613.0291 -8405 
2 0.5 3.11 ⋅ 10−10  -149625.24 -96768.292 
3 0.5 3.11 ⋅ 10−11  -99299.33 -86565.268 
4 0.5 3.11 ⋅ 10−12  -131845.09 -351291.28 
5 1.2 3.11 ⋅ 10−9  -9554.58 3850 
6 1.2 3.11 ⋅ 10−10  -36888.3 -19743.1 
7 1.2 3.11 ⋅ 10−11  -236071 -218326 
8 1.2 3.11 ⋅ 10−12  -315792 -854867 
9 3 3.11 ⋅ 10−9  -12963.9 8294 
10 3 3.11 ⋅ 10−10  -90457.6 -55203.4 
11 3 3.11 ⋅ 10−11  -587489 -558421 
12 3 3.11 ⋅ 10−12  -788077 -2149776 
13 5 3.11 ⋅ 10−9  -17705.2 9628.773 
14 5 3.11 ⋅ 10−10  -149625 -96768.3 
15 5 3.11 ⋅ 10−11  -977976 -936306 
16 5 3.11 ⋅ 10−12  -1315077 -3588563 
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